We are live on ! Find out more
INMB icon

INmune Bio
INMB

16 hedge funds and large institutions have $1.88M invested in INmune Bio in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

65% more capital invested

Capital invested by funds: $1.14M → $1.88M (+$740K)

23% more funds holding

Funds holding: 13 → 16 (+3)

0.12% more ownership

Funds ownership: 3.2% → 3.32% (+0.12%)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$201K
2
BlackRock
BlackRock
New York
+$15.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$6.83K
4
FIA
FNY Investment Advisers
New York
+$5.04K
5
PAG
Private Advisor Group
New Jersey
+$3.4K

Top Sellers

Rank Fund Capital Flow
1
FAIM
Financial Advocates Investment Management
Washington
-$88.1K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$38K
3
Victory Capital Management
Victory Capital Management
Texas
-$4K
4
UBS Group
UBS Group
Switzerland
-$1.56K
5
Osaic Holdings
Osaic Holdings
Arizona
-$504
Name Holding Trade Value Shares
Change 		Change in
Stake
FAIM
1
Financial Advocates Investment Management
Washington
$1.24M -$88.1K -17,500 -7%
Deutsche Bank
2
Deutsche Bank
Germany
$504K +$201K +40,000 +71%
BlackRock
3
BlackRock
New York
$98K +$15.4K +3,050 +19%
Bank of America
4
Bank of America
North Carolina
$9K +$65 +13 +0.8%
TRCT
5
Tower Research Capital (TRC)
New York
$7K +$6.83K +1,355 New
CCM
6
Covington Capital Management
California
$5K – – –
TPWA
7
TRUE Private Wealth Advisors
Oregon
$5K – – –
FIA
8
FNY Investment Advisers
New York
$5K +$5.04K +1,000 New
UBS Group
9
UBS Group
Switzerland
$4K -$1.56K -309 -27%
PAG
10
Private Advisor Group
New Jersey
$4K +$3.4K +675 New
Osaic Holdings
11
Osaic Holdings
Arizona
$1K -$504 -100 -33%
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$1K +$55 +11 +12%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$38K -11,443 Closed
Victory Capital Management
14
Victory Capital Management
Texas
– -$4K -1,460 Closed
Barclays
15
Barclays
United Kingdom
– +$5 +1 New
Wells Fargo
16
Wells Fargo
California
– +$5 +1 +5%
JP Morgan Chase
17
JP Morgan Chase
New York
– +$15 +3 New
Rockefeller Capital Management
18
Rockefeller Capital Management
New York
– +$252 +50 New

INMB Hedge Fund Activity: Q2 2020 in Review

16 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2020, worth a combined $1.88M — up 65% from $1.14M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INMB positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $201K. The largest seller was Financial Advocates Investment Management, cutting an estimated $88.1K.

  • 16 institutional investors held INmune Bio (INMB) as of Q2 2020, up from 13 in Q1 2020.
  • Funds reported $1.88M of INmune Bio stock for Q2 2020, up 65% quarter-over-quarter.
  • 6 funds opened new INmune Bio positions in Q2 2020 and 3 closed out, a net change of +3 holders.
  • The largest INmune Bio buyer in Q2 2020 was Deutsche Bank, an estimated $201K added.
  • The largest INmune Bio seller in Q2 2020 was Financial Advocates Investment Management, an estimated $88.1K sold.

Based on aggregated 13F filings for Q2 2020.